Investigating how a specific protein complex affects breast cancer progression
Official title: Role of the CTLH E3 ubiquitin ligase in breast cancer progression
Funded at University of Iowa · NIH-11052532 · Data updated 2026-11-12
This study is looking at how a specific protein complex affects the growth of HER2-positive breast cancers, which can be tough to treat, and aims to find new ways to make treatments work better for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $497,084 |
| NIH project number | 5R01CA282699-02 |
| Project ID | NIH-11052532 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with HER2-positive breast cancer who may be experiencing challenges with current therapies.
✕Less likely to help
Patients with non-HER2-positive breast cancer or those who are not currently undergoing treatment may not benefit from this research.
What this research studies
This research focuses on HER2-positive breast cancers, which are known for their aggressive nature and poor prognosis. The team aims to understand how a protein complex called the CTLH E3 ubiquitin ligase influences the progression of these cancers, particularly in relation to drug resistance against HER2-targeted therapies. By studying the signaling pathways involved, the researchers hope to identify new therapeutic targets that could enhance treatment effectiveness. Patients may benefit from insights that could lead to improved strategies for managing HER2-positive breast cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with HER2-positive breast cancer, potentially overcoming current drug resistance issues.
How similar studies have gone: Previous research has shown promise in targeting G protein coupled receptors in cancer treatment, suggesting that this approach may yield beneficial results.
Where this research is happening
-
University of Iowa
Iowa City, United States Active
Researchers
- Principal investigator: Chen, Songhai — University of Iowa
- Study coordinator: Chen, Songhai
Related research
Other NIH-funded projects on the same topics.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Translational breast cancer research to improve treatment options
A comprehensive program at Baylor College of Medicine is focusing on breast cancer; researchers will advance targeted therapies and biomarkers to help patients with aggressive or hard-to-treat forms.
-
Cancer Pain Management for Asian American Breast Cancer Survivors with Depressive Symptoms
A technology-based program helps Asian American breast cancer survivors with depressive symptoms manage chronic pain more effectively from home using a web app and mobile tools.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Gut bacteria and metabolites linked to breast density and cancer risk
A small, patient-friendly study will explore whether gut bacteria and their byproducts are connected to high breast density, which can raise cancer risk and make screening less accurate.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.